<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Integr Cancer Ther</journal-id><journal-id journal-id-type="iso-abbrev">Integr Cancer Ther</journal-id><journal-id journal-id-type="publisher-id">ICT</journal-id><journal-id journal-id-type="hwp">spict</journal-id><journal-title-group><journal-title>Integrative Cancer Therapies</journal-title></journal-title-group><issn pub-type="ppub">1534-7354</issn><issn pub-type="epub">1552-695X</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6142101</article-id><article-id pub-id-type="pmid">29431027</article-id><article-id pub-id-type="doi">10.1177/1534735418756736</article-id><article-id pub-id-type="publisher-id">10.1177_1534735418756736</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>A Controlled Trial of Sheng-Yu-Tang for Post&#x02013;Hematopoietic Stem Cell
Transplantation Leukemia Patients: A Proposed Protocol and Insights From a
Preliminary Pilot Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fleischer</surname><given-names>Tom</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1-1534735418756736">1</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Tung-Ti</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1-1534735418756736">1</xref><xref ref-type="aff" rid="aff2-1534735418756736">2</xref></contrib><contrib contrib-type="author"><name><surname>Chiang</surname><given-names>Jen-Huai</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff1-1534735418756736">1</xref><xref ref-type="aff" rid="aff2-1534735418756736">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0131-1658</contrib-id><name><surname>Yen</surname><given-names>Hung-Rong</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1-1534735418756736">1</xref><xref ref-type="aff" rid="aff2-1534735418756736">2</xref><xref ref-type="aff" rid="aff3-1534735418756736">3</xref><xref ref-type="corresp" rid="corresp1-1534735418756736"/></contrib></contrib-group><aff id="aff1-1534735418756736"><label>1</label>China Medical University, Taichung,
Taiwan</aff><aff id="aff2-1534735418756736"><label>2</label>China Medical University Hospital,
Taichung, Taiwan</aff><aff id="aff3-1534735418756736"><label>3</label>Asia University, Taichung, Taiwan</aff><author-notes><corresp id="corresp1-1534735418756736">Hung-Rong Yen, Research Center for
Traditional Chinese Medicine, Department of Medical Research and Department of
Chinese Medicine, China Medical University Hospital, 2 Yude Road, North
District, Taichung 404, Taiwan. Email:
<email>hungrongyen@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2018</year></pub-date><volume>17</volume><issue>3</issue><fpage>665</fpage><lpage>673</lpage><history><date date-type="received"><day>22</day><month>9</month><year>2017</year></date><date date-type="rev-recd"><day>9</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>9</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p><bold>Introduction:</bold> Hematopoietic stem cell transplantation has become a
well-established treatment for hematologic disorders including acute leukemia.
However, long-term survival rates following this procedure are still extremely
low, due to posttransplantation relapse, infections, and graft-versus-host
disease. We propose that adjunctive Chinese herbal medicine may benefit
posttransplantation patients. In preparation for a randomized clinical trial, we
conducted a pilot trial. <bold>Methods and Analysis:</bold> Between September
2015 and June 2017, 18 patients were consecutively enrolled at China Medical
University Hospital and followed for up to 1 year. Fresh blood samples were
obtained on a monthly basis, and immune reconstitution was analyzed. In addition
to the standard-care treatment administered by their oncologist, a number of
patients also received a Chinese herbal formula (Sheng-Yu-Tang) for up to 6
months. Results were used to improve on study protocol and estimate required
sample size for a future randomized trial. <bold>Ethics and
Dissemination:</bold> Study protocol was approved by the institutional
review board of China Medical University Hospital (DMR-105-005), and all
participants provided informed consent.</p></abstract><kwd-group><kwd>HSCT</kwd><kwd>acute leukemia</kwd><kwd>immune reconstitution</kwd><kwd>Chinese herbal medicine</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="section1-1534735418756736"><title>Introduction</title><p>Hematopoietic stem cell transplantation (HSCT) has become a well-established
treatment for hematologic disorders. Since its introduction in 1957, HSCT techniques
have improved, resulting in increased survival rates mainly due to a reduction in
organ damage and decreases in infection and severe acute graft-versus-host disease
(GVHD).<sup><xref rid="bibr1-1534735418756736" ref-type="bibr">1</xref>,<xref rid="bibr2-1534735418756736" ref-type="bibr">2</xref></sup>
In most high-risk acute leukemia patients, HSCT is the only treatment that offers
the prospect of long-term survival. This prospect, however, is still dismal, and
some studies suggest that 3-year overall survival in such patients is less than 20%.<sup><xref rid="bibr3-1534735418756736" ref-type="bibr">3</xref></sup> Relapse is still the main cause of death, and together with infections and
GVHD, it accounts for 65% to 70% of all posttransplantation mortality.<sup><xref rid="bibr4-1534735418756736" ref-type="bibr">4</xref></sup></p><p>A number of avenues have been explored to address these causes of mortality.
T-cell-depleted and CD34+-&#x0201c;enriched&#x0201d; grafts entail higher economic costs but are
still commonly used.<sup><xref rid="bibr5-1534735418756736" ref-type="bibr">5</xref>,<xref rid="bibr6-1534735418756736" ref-type="bibr">6</xref></sup>
These options tend to increase rates of engraftment while decreasing the rate of
GVHD, but they also result in prolonged immune reconstitution, putting patients at
higher risk of infection and relapse. Recent research has shone a spotlight on
natural killer (NK) cells and &#x003b3;&#x003b4; T cells, which might be helpful in the fight
against viral infections and may improve graft-versus-leukemia responses.<sup><xref rid="bibr7-1534735418756736" ref-type="bibr">7</xref></sup> Along this same line of reasoning, recent graft manipulation approaches
include the depletion of CD19+ and &#x003b1;&#x003b2; T cells.<sup><xref rid="bibr8-1534735418756736" ref-type="bibr">8</xref>,<xref rid="bibr9-1534735418756736" ref-type="bibr">9</xref></sup> These techniques emphasize the
key role that immunoregulation likely plays in necessary improvements in post-HSCT
mortality rates.</p><p>We wondered whether the immunoregulatory properties attributed to some Chinese herbal
medicines (CHM) could curtail these mortality rates. Many cell line and animal model
studies have demonstrated that some CHM exert favorable effects on the immune
system. For instance, extracts of <italic>Angelica sinensis</italic> (dang gui) have
been shown to induce the activation and proliferation of &#x003b3;&#x003b4; T cells;<sup><xref rid="bibr10-1534735418756736" ref-type="bibr">10</xref></sup>
<italic>Astragalus membranaceus</italic> (huang qi) can both prompt the
proliferation of and mitigate the effects of immunosuppressive agents on bone marrow
CD34+ cells.<sup><xref rid="bibr11-1534735418756736" ref-type="bibr">11</xref></sup> Epidemiological studies have shown that there are correlations between
prolonged survival times and the use of CHM among leukemia patients.<sup><xref rid="bibr12-1534735418756736" ref-type="bibr">12</xref><xref rid="bibr13-1534735418756736" ref-type="bibr"/>-<xref rid="bibr14-1534735418756736" ref-type="bibr">14</xref></sup> Although few such studies have
been published in peer-reviewed journals, a handful of clinical studies have been
conducted in China regarding the use of CHM in post-HSCT leukemia patients, and
these have achieved positive results.<sup><xref rid="bibr15-1534735418756736" ref-type="bibr">15</xref></sup></p><p>Due to the poor prognosis of high-risk leukemia HSCT patients and the seemingly
positive potential of CHM, we employed a more rigorous clinical study to evaluate
the efficacy of this treatment. We obtained blood samples from patients to measure
the influence of CHM on immune reconstitution. Various methodological and logistical
aspects of the trial posed new challenges to our group, and we were therefore
motivated to perform a feasibility study.</p></sec><sec sec-type="methods" id="section2-1534735418756736"><title>Methods</title><sec id="section3-1534735418756736"><title>Chinese Herbal Formulation</title><p>Following a review of existing studies and in combination with our own clinical knowledge,<sup><xref rid="bibr15-1534735418756736" ref-type="bibr">15</xref></sup> we chose to use the CHM formulation Sheng-Yu-Tang (&#x08056;&#x06108;&#x06e6f;, SYT; <xref rid="table1-1534735418756736" ref-type="table">Table 1</xref>), which was
administered without a personalized diagnosis. This formula is fairly simple (6
ingredients) and is composed of herbs that have been extensively studied.
Moreover, and as explained in our previous publication, this formula embodies
the core treatment strategy that seems to be ideal in the vast majority of
post-HSCT patients from a Chinese medicine perspective.<sup><xref rid="bibr15-1534735418756736" ref-type="bibr">15</xref></sup></p><table-wrap id="table1-1534735418756736" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Constituents of the Sheng-Yu-Tang Formulation as Produced by Sun Ten Pharmaceutical<sup><xref ref-type="table-fn" rid="table-fn1-1534735418756736">a</xref></sup>.</p></caption><alternatives><graphic xlink:href="10.1177_1534735418756736-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Pinyin Name</th><th align="center" rowspan="1" colspan="1">Latin Name</th><th align="center" rowspan="1" colspan="1">Amount</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Di Huang</td><td rowspan="1" colspan="1">
<italic>Rehmannia glutinosa</italic>
</td><td rowspan="1" colspan="1">5 g</td></tr><tr><td rowspan="1" colspan="1">Chuan Xiong</td><td rowspan="1" colspan="1">
<italic>Ligusticum chuanxiong</italic>
</td><td rowspan="1" colspan="1">2.5 g</td></tr><tr><td rowspan="1" colspan="1">Ren Shen</td><td rowspan="1" colspan="1">
<italic>Panax ginseng</italic>
</td><td rowspan="1" colspan="1">5 g</td></tr><tr><td rowspan="1" colspan="1">Dang Gui</td><td rowspan="1" colspan="1">
<italic>Angelica sinensis</italic>
</td><td rowspan="1" colspan="1">2.5 g</td></tr><tr><td rowspan="1" colspan="1">Bai Shao</td><td rowspan="1" colspan="1">
<italic>Paeonia lactiflora</italic>
</td><td rowspan="1" colspan="1">5 g</td></tr><tr><td rowspan="1" colspan="1">Huang Qi</td><td rowspan="1" colspan="1">
<italic>Astragalus membranaceus</italic>
</td><td rowspan="1" colspan="1">5 g</td></tr><tr><td colspan="3" rowspan="1">Extracts from the above are concentrated into 8
g</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Powdered fibers</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">5.7 g</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Starch</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2.8 g</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">16.5 g</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1534735418756736"><label>a</label><p>This product is registered with the Taiwanese Ministry of Health and
Welfare under serial number 047770.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section4-1534735418756736"><title>Inclusion and Exclusion Criteria</title><p>Patients should be (1) &#x02265;20 years of age; (2) diagnosed with acute lymphocytic
leukemia, acute myeloid leukemia, or myelodysplastic syndrome; and (3) eligible
for allogeneic blood stem cell transplantation in accordance with the criteria
of the local institution and the attending physician. Patients must also agree
to comply with all study requirements. Patients should be excluded from the
trial if they receive CHM from other sources.</p></sec><sec id="section5-1534735418756736"><title>Design</title><p>Patients were enrolled by signing a consent form prior to transplantation. Three
months following transplantation, upon consent, patients were allocated to the
SYT group. Patients who were not interested in taking SYT were allocated to the
control group. Both groups continued to receive standard biomedical care from
their oncologist. Patients allocated to the treatment group were to receive a
batch of SYT once each month for a duration of 6 months. Peripheral blood
samples were collected and analyzed on a monthly basis.</p></sec><sec id="section6-1534735418756736"><title>Sample Size and Statistical Analysis</title><p>Estimations of power size were performed using the &#x0201c;diggle.linear.power&#x0201d; of the
&#x0201c;longpower&#x0201d; package of R Version 3.4.0 (R Core Team, 2015). A general estimation
equation (GEE) model with a normal distribution, identity function, and
unstructured working correlation matrix structure was used on selected outcomes
of the patients followed in the study. We estimate that a minimum of 10 patients
in each group would be required for achieving statistical significance.
According to our preliminary results (described below), although none of the
patients dropped out of the trial, the mortality rate was roughly 38%, and only
33% of patients who commenced herbal treatment persisted for &#x0003e;30 days. We
therefore estimate that the recruitment of 50 patients in each group (n = 100)
should be sufficient for a randomized controlled trial. The data from patients
receiving SYT for 30 days or less who then cease its use for any reason should
be excluded from analysis. Similarly, data of patients from the control group
who expire prior to the 4 month posttransplantation time point should be
excluded from analysis. The remaining data should be analyzed according to an
intention-to-treat approach.</p></sec><sec id="section7-1534735418756736"><title>Outcome Measures</title><p>The main outcome measured in this study is the immune reconstitution rate of key
cell populations, which is measured using flow cytometry with peripheral blood
samples. If possible, records of minimal residual disease (MRD) from bone marrow
aspirations and the occurrence rate of opportunistic infections, hospitalization
frequency, and relapse rates should be obtained and considered secondary outcome
measures. An additional secondary outcome measure is the EORTC QLQ-C30
questionnaire.</p><p>For immune reconstitution, other than CD4+ and CD8+ T cells, the following cell
compartments are to be analyzed.</p><sec id="section8-1534735418756736"><title>NK Cells</title><p>NK cells are among the first population of cells to recuperate following
transplantation and play an important role as first-line response against
viral infections.<sup><xref rid="bibr16-1534735418756736" ref-type="bibr">16</xref></sup> First NK subset to recover express CD56<sup>bright</sup>CD16&#x02212; and are
derived from hematopoietic CD34+ cells, which give rise to
CD56<sup>dim</sup>CD16+, which have cytotoxic capabilities. These are
found mostly in peripheral blood.<sup><xref rid="bibr17-1534735418756736" ref-type="bibr">17</xref></sup> Furthermore, NK cell transfusions following HSCT have been shown in
some groups to reduce the relapse of acute myeloid leukemia, decrease GVHD,
and improve engraftment and the overall survival.<sup><xref rid="bibr18-1534735418756736" ref-type="bibr">18</xref></sup></p></sec><sec id="section9-1534735418756736"><title>T Regulatory Cells</title><p>The incidence of either MRD+ or relapse in patients with a high frequency of
CD4+CD25&#x02212;CD69+ T cells (&#x0003e;7%) has been reported to be significantly higher
than that of patients with a low frequency of CD4+CD25&#x02212;CD69+ T cells at +60
days, +90 days, and +270 days after transplant.<sup><xref rid="bibr19-1534735418756736" ref-type="bibr">19</xref></sup> Also, in vitro and animal models have shown that the increase of
donor CD4+CD25+ T regulatory cells can suppress the early expansion of
alloreactive T cells&#x02014;a hallmark of acute GVHD.<sup><xref rid="bibr20-1534735418756736" ref-type="bibr">20</xref></sup> Clinical studies that have adopted this treatment principle have
shown that infusion of donor T regulatory cells can prevent GVHD while
favoring the reconstitution of regular T cells.<sup><xref rid="bibr21-1534735418756736" ref-type="bibr">21</xref></sup></p></sec><sec id="section10-1534735418756736"><title>&#x003b3;&#x003b4; T Cells</title><p>Gamma delta T cells have been described as a link between the adaptive and
innate immune responses, because it has already been shown that &#x003b3;&#x003b4; T cell
reconstitution is associated with fewer infections and improved event-free
survival after hematopoietic stem cell transplantation.<sup><xref rid="bibr22-1534735418756736" ref-type="bibr">22</xref>,<xref rid="bibr23-1534735418756736" ref-type="bibr">23</xref></sup></p></sec><sec id="section11-1534735418756736"><title>B Cells</title><p>Na&#x000ef;ve B cells are the first B cell subset to return to their normal values,
approximately 6 months posttransplantation. The counts of memory B cells,
however, might be low for up to 2 years post-HSCT.<sup><xref rid="bibr24-1534735418756736" ref-type="bibr">24</xref></sup> Delayed B cell reconstitution has been associated with GVHD, and
impaired immunoglobulin gene rearrangement render HSCT patients susceptible
to various bacteria and viruses.<sup><xref rid="bibr25-1534735418756736" ref-type="bibr">25</xref>,<xref rid="bibr26-1534735418756736" ref-type="bibr">26</xref></sup></p></sec><sec id="section12-1534735418756736"><title>Dendritic Cells</title><p>In peripheral blood stem cell transplantations, it has been shown that there
is a relationship between a low dendritic cell count in the first 3 to 4
months following transplant, and disease relapse, acute GVHD, and death.<sup><xref rid="bibr27-1534735418756736" ref-type="bibr">27</xref></sup></p></sec></sec><sec id="section13-1534735418756736"><title>Flow Cytometry</title><p>Approximately 5 mL of peripheral blood should be collected in heparin tubes (BD
Biosciences, San Jose, CA, USA) and placed on a rotary plate overnight at 10
rpm. Peripheral blood mononuclear cells (PBMC) can be isolated from whole blood
using Ficoll-Paque PLUS (GE Healthcare Life Sciences, Uppsala, Sweden). To
induce cytokine production, cells should be stimulated with
paramethoxyamphetamine (50 ng/mL; Sigma-Aldrich, St Louis, MO, USA), ionomycin
(500 ng/mL; Sigma-Aldrich, St Louis, MO, USA), and GolgiStop (1:1000; BD
Biosciences, San Jose, CA, USA) for 5 hours. The following antibodies may be
used: Foxp3, CD11c (BD Bioscience, Franklin Lakes, NJ, USA), IFN-&#x003b3;, CD8 (Beckman
Coulter, Mississauga, ON, Canada), CD3, CD4, CD45RA, CD62L, T cell receptor
(TCR) &#x003b3;/&#x003b4;, CD56, CD16, CD19, CD27, IgD, CD14, CD25, and IL-17 (Biolegend, San
Diego, CA, USA).</p></sec><sec id="section14-1534735418756736"><title>Enzyme-Linked Immunosorbent Assay</title><p>PBMC obtained from patients were seeded (2 &#x000d7; 10<sup>6</sup>) in 96-well
rounded-bottom plates using Iscove&#x02019;s Modified Dulbecco&#x02019;s Medium containing 5%
fetal bovine serum (Gibco, MA, USA) at 37&#x000b0;C and 5% CO<sub>2</sub>. Cells were
co-cultured for 24 and 48 hours with SYT (50, 100, and 200 &#x000b5;g/mL),
paramethoxyamphetamine 50 ng/mL (Sigma-Aldrich), and ionomycin 500 ng/mL
(Sigma-Aldrich). The concentrations of IL-2, TNF-&#x003b1;, and IFN-&#x003b3; were measured
using the appropriate ELISA (enzyme-linked immunosorbent assay) kits (BD
Biosciences, San Jose, CA, USA) as per manufacturer&#x02019;s instructions.</p></sec><sec id="section15-1534735418756736"><title>Safety</title><p>No adverse events related to SYT occurred in our pilot study. In a future
protocol, all adverse events are to be recorded regardless of the possible
association to herbal treatment. Herbal treatment is to be discontinued if
either the attending oncologist or the trial investigator believes that the
patient may be at risk of harm, including disability, hospitalization, or
death.</p></sec></sec><sec id="section16-1534735418756736"><title>Preliminary Results</title><sec id="section17-1534735418756736"><title>Patients</title><p>Patients from the Division of Hematology and Oncology of the China Medical
University Hospital were consecutively enrolled in the trial from September 1,
2015, onwards. The study protocol was approved by the Institutional Review Board
of the China Medical University Hospital (DMR-105-005), and all participants
provided informed consent. The trial protocol was made public on <ext-link ext-link-type="uri" xlink:href="http://clincaltrials.gov">clincaltrials.gov</ext-link> (identifier NCT02580071).</p></sec><sec id="section18-1534735418756736"><title>Chinese Herbal Formulation</title><p>Granulated SYT was purchased from the Sun Ten Pharmaceutical Co, Ltd, Taiwan
(product license #047770) and packaged as 90 portions per batch. Patients
received 1 batch per month and were instructed to take 1 portion (4.2 g) 3 times
a day. Before enrollment, patients were explained that they were expected to
take SYT for 6 months.</p></sec><sec id="section19-1534735418756736"><title>Clinical Experiences</title><p>We recruited 18 patients in a nonrandomized consecutive manner since November
2015 until May 2017 (<xref rid="table2-1534735418756736" ref-type="table">Table
2</xref>). Our goals have been to test the feasibility of the proposed
protocol and to assess the compliance rate of patients and the adequacy of our
inclusion and exclusion criteria, among other factors, with the intention of
building on these insights to conduct a more comprehensive randomized trial.<sup><xref rid="bibr28-1534735418756736" ref-type="bibr">28</xref></sup></p><table-wrap id="table2-1534735418756736" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Patient Characteristics.</p></caption><alternatives><graphic xlink:href="10.1177_1534735418756736-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Patient #</th><th align="center" rowspan="1" colspan="1">Age</th><th align="center" rowspan="1" colspan="1">Gender</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Condition</th><th align="center" rowspan="1" colspan="1">Comment</th><th align="center" rowspan="1" colspan="1">Donor</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">AML</td><td rowspan="1" colspan="1">FLT3 (+), second HSCT</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">T-ALL</td><td rowspan="1" colspan="1">BCR-ABL (+)</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">MDS-AML</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">ALL</td><td rowspan="1" colspan="1">BCR-ABL (+)</td><td rowspan="1" colspan="1">MUD</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">AML</td><td rowspan="1" colspan="1">FLT3 (&#x02212;)</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">MDS</td><td rowspan="1" colspan="1">RAEB-T</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">B-ALL/LBL</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">MUD</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">AML</td><td rowspan="1" colspan="1">FLT3 (&#x02212;)</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">MDS-AML</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">MDS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">MUD</td></tr><tr><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">MDS</td><td rowspan="1" colspan="1">RAEB-1</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">AML</td><td rowspan="1" colspan="1">FLT3/ITD (+)</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">MDS</td><td rowspan="1" colspan="1">del(20)(q1.2) RAEB</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">AML</td><td rowspan="1" colspan="1">FLT3 (&#x02212;), del(9)</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Treatment</td><td rowspan="1" colspan="1">T-ALL</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">MUD</td></tr><tr><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">SAA-AML</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">MUD</td></tr><tr><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">AML</td><td rowspan="1" colspan="1">FLT3/ITD(+), NPM1(+),PML RARa (&#x02212;)</td><td rowspan="1" colspan="1">MSD</td></tr><tr><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">Control</td><td rowspan="1" colspan="1">ALL</td><td rowspan="1" colspan="1">i (9) (q10), CD20+</td><td rowspan="1" colspan="1">MSD</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-1534735418756736"><p>Abbreviations: AML, acute myeloid leukemia; FLT3, fms-like tyrosine
kinase 3; HSCT, hematopoietic stem cell transplantation; MSD,
matched sibling donor; T-ALL, T cell acute lymphoblastic leukemia;
BCR-ABL, the fusion gene on the Philadelphia (Ph) chromosome; MDS,
myelodysplastic syndrome; ALL, acute lymphocytic leukemia; MUD,
matched unrelated donor; RAEB, refractory anemia with excess of
blast; B-ALL/LBL, B lymphoblastic leukemia/lymphoma; ITD, internal
tandem duplication; SAA, severe aplastic anemia; NPM, nucleophosmin;
PML RARa, promyelocytic leukemia/retinoic acid receptor alpha.</p></fn></table-wrap-foot></table-wrap><p>Of the 7 patients who were assigned to receive SYT, only 2 continued for &#x0003e;30
days. Reasons for discontinuation included persistent leukopenia, herpes zoster,
and relapse. We were aware of at least 2 other patients enrolled in the trial
who did not receive SYT but sought CHM treatment elsewhere.</p><p>Despite the small sample size and the inability to demonstrate efficacy or
effectiveness through statistical means, we analyzed our preliminary data. These
data demonstrate the feasibility of the methods applied here to distinguish
differences in the immune reconstitution of both trial groups (<xref ref-type="fig" rid="fig1-1534735418756736">Figures 1</xref> and <xref ref-type="fig" rid="fig2-1534735418756736">2</xref>).</p><fig id="fig1-1534735418756736" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Average differences in immune reconstitution of CD4+ and CD8+ T cells.
Patient sample size of current data is insufficient to draw conclusions;
however, these data demonstrate the possible contribution of this type
of analysis. There is, for example, a distinct difference in relative
proportion of CD4+ na&#x000ef;ve cells and CD8+ terminally differentiated cells,
between the 2 groups. Missing columns represent time points at which no
samples were collected from any patients.</p><p>Abbreviations: TCM, traditional Chinese medicine; PT, pretransplantation;
CM, central memory; EM, effector memory; TEMRA, terminally
differentiated effector memory.</p></caption><graphic xlink:href="10.1177_1534735418756736-fig1"/></fig><fig id="fig2-1534735418756736" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Immune reconstitution of various other cell compartments. Because there
is no certain way to predict in advance which, if any, subset of cells
will be affected by Sheng-Yu-Tang, it would be preferable to track the
reconstitution of as many cell compartments as possible.</p><p>Abbreviations: TCM, traditional Chinese medicine; PT, pretransplantation;
NK, natural killer.</p></caption><graphic xlink:href="10.1177_1534735418756736-fig2"/></fig><p>We also studied the in vitro effects of SYT on patient unsorted PBMC with regard
to the secretion of IL-2, IFN-&#x003b3;, and TNF-&#x003b1;, which are representative cytokines
of the TH1 subset that are known to be directly related to graft-versus-leukemia
and GVHD (<xref ref-type="fig" rid="fig3-1534735418756736">Figure 3</xref>).<sup><xref rid="bibr29-1534735418756736" ref-type="bibr">29</xref></sup> Due to the small sample size of measurements, we did not achieve
statistical significance, and the only distinguishable trend was a decrease in
TNF-&#x003b1;. GVHD is a result of the interplay between multiple types of cell
components and cytokines, but TNF-&#x003b1; plays a central role, and its reduction is
known to decrease the symptoms of GVHD.<sup><xref rid="bibr30-1534735418756736" ref-type="bibr">30</xref>,<xref rid="bibr31-1534735418756736" ref-type="bibr">31</xref></sup> Whether this implies that
SYT may mitigate GVHD requires further investigation. This type of in vitro
examination should be considered exploratory as it is unlikely that a simple
increase or decrease in a single signaling factor is predictive of the clinical
outcome. IL-2, for example, may induce the proliferation of T cells,
exacerbating post-HSCT on one hand and inducing immunosuppression via T
regulatory cells on the other.<sup><xref rid="bibr32-1534735418756736" ref-type="bibr">32</xref><xref rid="bibr33-1534735418756736" ref-type="bibr"/>-<xref rid="bibr34-1534735418756736" ref-type="bibr">34</xref></sup> This assay is thus not
defined as an outcome measure, though it might provide complementary insight to
other observations from the trial.</p><fig id="fig3-1534735418756736" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Secretion of IL-2, TNF-&#x003b1;, and IFN-&#x003b3; by peripheral blood mononuclear cells
obtained from 7 patients, following in vitro co-culture with
Sheng-Yu-Tang. None of the differences between any 2 columns reached
significance level; however, a possible trend may be observed in the
concentration levels of TNF-&#x003b1;.</p></caption><graphic xlink:href="10.1177_1534735418756736-fig3"/></fig></sec></sec><sec sec-type="discussion" id="section20-1534735418756736"><title>Discussion</title><p>Mortality was not chosen as a primary outcome measure for this study for a number of
reasons. First, the prognoses of affected patients vary widely according to numerous
factors, such as severity of disease, gender, genetic and molecular abnormalities,
as well as donor type (ie, familial relationships and HLA-matching).<sup><xref rid="bibr35-1534735418756736" ref-type="bibr">35</xref></sup> No data that we know of suggest different rates of immune reconstitution
according to disease, and other recently published studies have excluded the
consideration of these factors in their study design.<sup><xref rid="bibr36-1534735418756736" ref-type="bibr">36</xref>,<xref rid="bibr37-1534735418756736" ref-type="bibr">37</xref></sup> Second, as most deaths occur
within the first 2 years of HSCT, measuring mortality would require an additional
year of follow-up. Measurement of immune reconstitution allows for the simultaneous
assessment of multiple factors and offers insights concerning the possible
mechanisms of action of the intervention.</p><p>No consensus exists regarding the ideal sampling rate for measurement of long-term
immune reconstitution. In the protocol described above, we obtained peripheral blood
samples from patients monthly, over the course of 1 year. Currently, we believe that
6 samples over the course of 1 year should be adequate, and other recently published
studies have also followed this protocol (<xref ref-type="fig" rid="fig4-1534735418756736">Figure 4</xref>).<sup><xref rid="bibr36-1534735418756736" ref-type="bibr">36</xref></sup> With regard to the inclusion criteria, we originally intended this study to
focus on patients with acute leukemia. However, since the total number of patients
that undergo allo-HSCT is limited, we suggest a revision of this condition to open
the trial to all patients undergoing allo-HSCT. As noted above, different disease
diagnoses should have no effect on the rate of immune reconstitution.</p><fig id="fig4-1534735418756736" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Suggested design for future controlled trial. One-hundred patients are to be
randomized to control or treatment group, 3 months following
transplantation. Peripheral blood samples will be obtained at months 1, 2,
3, 6, 9, and 12 (noted in figure by the blood vial).</p><p>Abbreviation: SYT, Sheng-Yu-Tang herbal formula.</p></caption><graphic xlink:href="10.1177_1534735418756736-fig4"/></fig><p>While designing this study, we were uncertain about the appropriate monetary
incentive to use to motivate patients to enroll. We found that many patients were
indifferent toward this incentive and that the backing of the respective attending
oncologist was the most crucial factor for enrollment. This is understandable in
light of the decisions and repercussions these patients face. The processing of
blood samples together with the monetary incentive for patients per sample
constituted a major portion of the resources required for this study, and their
revision directly relates to the feasibility of a larger trial.</p><p>In its acute form, GVHD commonly presents within the first 100 days post-HSCT. In all
trials we reviewed that were conducted in China, herbal treatment was administered
during this period. To avoid unnecessary risk, the initiation of herbal treatment in
this protocol was defined as 3 months following transplantation. Herbal treatment
should be discontinued in the case of manifestation of moderate to severe chronic
GVHD per the assessment of the attending oncologist. In our preliminary trial,
patients were offered to continue receiving herbal medicine after the alleviation of
GVHD if they were able to complete the treatment course prior to the 1-year
posttransplantation time point. We believe future trial protocols should adopt this
option.</p><p>Chronic kidney disease (CKD) should be acknowledged twice in the context of an
allo-HSCT clinical study design. Decline in renal function is common among post-HSCT
patients and may progress into CKD. Incidence rates of CKD among studies are highly
variable, with values ranging from 13% to 66%.<sup><xref rid="bibr38-1534735418756736" ref-type="bibr">38</xref>,<xref rid="bibr39-1534735418756736" ref-type="bibr">39</xref></sup> The main implication of
post-HSCT renal damage is the due diligence that should be exercised when
administering herbal medicine. Basic research demonstrates that <italic>Rehmannia
glutinosa</italic> and the combination of <italic>Astragalus
membranaceus</italic> and <italic>Angelica sinensis</italic>&#x02014;constituents of
SYT&#x02014;may actually exert a renoprotective effect. However, until further evidence is
collected, it is impossible to rule out potentially deleterious drug
interactions.<sup><xref rid="bibr40-1534735418756736" ref-type="bibr">40</xref>,<xref rid="bibr41-1534735418756736" ref-type="bibr">41</xref></sup> In our preliminary study, we determined that the administration
of SYT to patients would be reassessed in cases where the glomerular filtration rate
dropped below 50 mL/min/1.73 m<sup>2</sup> or if serum creatinine levels rose to
double that of baseline. Adequate consideration should also be given to patients
with pretransplantation kidney disorders. Abnormal renal function is considered a
major risk factor for HSCT. However, collective experience and practices among
institutions may strongly vary.<sup><xref rid="bibr42-1534735418756736" ref-type="bibr">42</xref>,<xref rid="bibr43-1534735418756736" ref-type="bibr">43</xref></sup> Although renal function does
not appear in the above-mentioned inclusion/exclusion criteria, these should be
explicitly defined in cooperation with the oncologists participating in the trial,
in order to avoid the occurrence of selection bias and survivorship bias.</p></sec><sec sec-type="conclusions" id="section21-1534735418756736"><title>Conclusion</title><p>The results of this pilot study suggest that a larger and more rigorous trial is
feasible. Revisions to the inclusion criteria, immune reconstitution sampling rate,
and monetary incentive to patients should make for a more manageable protocol.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Authors&#x02019; Note:</bold> If any reader is interested in individual participant data that underlie the
results reported in this article, the authors have no objection to share these,
after de-identification, and requests will be considered on request.</p></fn><fn fn-type="other"><p><bold>Trial Registration:</bold>
<ext-link ext-link-type="uri" xlink:href="http://Clincaltrials.gov">Clincaltrials.gov</ext-link> identifier NCT02580071.</p></fn><fn fn-type="other"><p><bold>Author Contributions:</bold> Drafting of manuscript: TF. Study design: TF, TTC, and HRY. Data collection and
analysis: TF. Statistical analyses: JHC. Critical revision of the manuscript for
intellectual content: TF, TTC, and HRY.</p></fn><fn fn-type="COI-statement"><p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This study was
supported by China Medical University under the Aim for Top University Plan of
the Ministry of Education, Taiwan. This study was also supported in part by
China Medical University Hospital, Taiwan (DMR-105-005) and the Taiwan Ministry
of Health and Welfare Clinical Trial and Research Center of Excellence
(MOHW106-TDU-B-212-113004). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the article.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Hung-Rong Yen&#x02009;<inline-graphic xlink:href="10.1177_1534735418756736-img1.jpg"/>&#x02009;<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-0131-1658">https://orcid.org/0000-0002-0131-1658</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1534735418756736"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gooley</surname><given-names>TA</given-names></name><name><surname>Chien</surname><given-names>JW</given-names></name><name><surname>Pergam</surname><given-names>SA</given-names></name><etal>et al</etal></person-group>
<article-title>Reduced mortality after allogeneic
hematopoietic-cell transplantation</article-title>. <source>N Engl J
Med</source>.
<year>2010</year>;<volume>363</volume>:<fpage>2091</fpage>-<lpage>2101</lpage>.<pub-id pub-id-type="pmid">21105791</pub-id></mixed-citation></ref><ref id="bibr2-1534735418756736"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Kurosawa</surname><given-names>S</given-names></name><name><surname>Tajima</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Analysis of non-relapse mortality and causes of
death over 15 years following allogeneic hematopoietic stem cell
transplantation</article-title>. <source>Bone Marrow Transplant</source>.
<year>2016</year>;<volume>51</volume>:<fpage>553</fpage>-<lpage>559</lpage>.<pub-id pub-id-type="pmid">26752142</pub-id></mixed-citation></ref><ref id="bibr3-1534735418756736"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duval</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>JP</given-names></name><name><surname>He</surname><given-names>W</given-names></name><etal>et al</etal></person-group>
<article-title>Hematopoietic stem-cell transplantation for
acute leukemia in relapse or primary induction failure</article-title>.
<source>J Clin Oncol</source>.
<year>2010</year>;<volume>28</volume>:<fpage>3730</fpage>-<lpage>3738</lpage>.<pub-id pub-id-type="pmid">20625136</pub-id></mixed-citation></ref><ref id="bibr4-1534735418756736"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barrett</surname><given-names>AJ</given-names></name><name><surname>Battiwalla</surname><given-names>M</given-names></name></person-group>
<article-title>Relapse after allogeneic stem cell
transplantation</article-title>. <source>Expert Rev Hematol</source>.
<year>2010</year>;<volume>3</volume>:<fpage>429</fpage>-<lpage>441</lpage>.<pub-id pub-id-type="pmid">21083034</pub-id></mixed-citation></ref><ref id="bibr5-1534735418756736"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aversa</surname><given-names>F</given-names></name><name><surname>Tabilio</surname><given-names>A</given-names></name><name><surname>Velardi</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Treatment of high-risk acute leukemia with
T-cell-depleted stem cells from related donors with one fully mismatched HLA
haplotype</article-title>. <source>N Engl J Med</source>.
<year>1998</year>;<volume>339</volume>:<fpage>1186</fpage>-<lpage>1193</lpage>.<pub-id pub-id-type="pmid">9780338</pub-id></mixed-citation></ref><ref id="bibr6-1534735418756736"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aversa</surname><given-names>F</given-names></name><name><surname>Terenzi</surname><given-names>A</given-names></name><name><surname>Tabilio</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Full haplotype-mismatched hematopoietic
stem-cell transplantation: a phase II study in patients with acute leukemia
at high risk of relapse</article-title>. <source>J Clin Oncol</source>.
<year>2005</year>;<volume>23</volume>:<fpage>3447</fpage>-<lpage>3454</lpage>.<pub-id pub-id-type="pmid">15753458</pub-id></mixed-citation></ref><ref id="bibr7-1534735418756736"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheper</surname><given-names>W</given-names></name><name><surname>Grunder</surname><given-names>C</given-names></name><name><surname>Straetemans</surname><given-names>T</given-names></name><name><surname>Sebestyen</surname><given-names>Z</given-names></name><name><surname>Kuball</surname><given-names>J</given-names></name></person-group>
<article-title>Hunting for clinical translation with
innate-like immune cells and their receptors</article-title>.
<source>Leukemia</source>.
<year>2014</year>;<volume>28</volume>:<fpage>1181</fpage>-<lpage>1190</lpage>.<pub-id pub-id-type="pmid">24345790</pub-id></mixed-citation></ref><ref id="bibr8-1534735418756736"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Bauquet</surname><given-names>A</given-names></name><name><surname>Palumbo</surname><given-names>G</given-names></name><name><surname>Moretta</surname><given-names>F</given-names></name><name><surname>Bertaina</surname><given-names>A</given-names></name></person-group>
<article-title>Negative depletion of &#x003b1;/&#x003b2;+ T cells and of CD19+
B lymphocytes: a novel frontier to optimize the effect of innate immunity in
HLA-mismatched hematopoietic stem cell transplantation</article-title>.
<source>Immunol Lett</source>.
<year>2013</year>;<volume>155</volume>:<fpage>21</fpage>-<lpage>23</lpage>.<pub-id pub-id-type="pmid">24091162</pub-id></mixed-citation></ref><ref id="bibr9-1534735418756736"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schumm</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>P</given-names></name><name><surname>Bethge</surname><given-names>W</given-names></name><etal>et al</etal></person-group>
<article-title>Depletion of T-cell receptor alpha/beta and CD19
positive cells from apheresis products with the CliniMACS
device</article-title>. <source>Cytotherapy</source>.
<year>2013</year>;<volume>15</volume>:<fpage>1253</fpage>-<lpage>1258</lpage>.<pub-id pub-id-type="pmid">23993299</pub-id></mixed-citation></ref><ref id="bibr10-1534735418756736"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holderness</surname><given-names>J</given-names></name><name><surname>Jackiw</surname><given-names>L</given-names></name><name><surname>Kimmel</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Select plant tannins induce IL-2Ralpha
up-regulation and augment cell division in gammadelta T
cells</article-title>. <source>J Immunol</source>.
<year>2007</year>;<volume>179</volume>:<fpage>6468</fpage>-<lpage>6478</lpage>.<pub-id pub-id-type="pmid">17982035</pub-id></mixed-citation></ref><ref id="bibr11-1534735418756736"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ismail</surname><given-names>ZM</given-names></name><name><surname>Amin</surname><given-names>NM</given-names></name><name><surname>Yacoub</surname><given-names>MF</given-names></name><name><surname>Mohamed</surname><given-names>AM</given-names></name></person-group>
<article-title>Myelo-enhancement by astragalus membranaceus in
male albino rats with chemotherapy myelo-suppression. Histological and
immunohistochemical study</article-title>. <source>Int J Stem
Cells</source>.
<year>2014</year>;<volume>7</volume>:<fpage>12</fpage>-<lpage>22</lpage>.<pub-id pub-id-type="pmid">24921023</pub-id></mixed-citation></ref><ref id="bibr12-1534735418756736"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fleischer</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Chiang</surname><given-names>JH</given-names></name><name><surname>Sun</surname><given-names>MF</given-names></name><name><surname>Yen</surname><given-names>HR</given-names></name></person-group>
<article-title>Improved survival with integration of Chinese
herbal medicine therapy in patients with acute myeloid leukemia: a
nationwide population-based cohort study</article-title>. <source>Integr
Cancer Ther</source>.
<year>2017</year>;<volume>16</volume>:<fpage>156</fpage>-<lpage>164</lpage>.<pub-id pub-id-type="pmid">27531548</pub-id></mixed-citation></ref><ref id="bibr13-1534735418756736"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yen</surname><given-names>HR</given-names></name><name><surname>Lai</surname><given-names>WY</given-names></name><name><surname>Muo</surname><given-names>CH</given-names></name><name><surname>Sun</surname><given-names>MF</given-names></name></person-group>
<article-title>Characteristics of traditional Chinese medicine
use in pediatric cancer patients: a nationwide, retrospective,
Taiwanese-registry, population-based study</article-title>. <source>Integr
Cancer Ther</source>.
<year>2017</year>;<volume>16</volume>:<fpage>147</fpage>-<lpage>155</lpage>.<pub-id pub-id-type="pmid">27405933</pub-id></mixed-citation></ref><ref id="bibr14-1534735418756736"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuo</surname><given-names>YT</given-names></name><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Muo</surname><given-names>CH</given-names></name><etal>et al</etal></person-group>
<article-title>Use of complementary traditional Chinese
medicines by adult cancer patients in Taiwan: a nationwide population-based
study</article-title> [published online <month>6</month>
<day>1</day>, <year>2017</year>]. <source>Integr Cancer Ther</source>.
doi:<pub-id pub-id-type="doi">10.1177/1534735417716302.</pub-id></mixed-citation></ref><ref id="bibr15-1534735418756736"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fleischer</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Yen</surname><given-names>HR</given-names></name></person-group>
<article-title>Post-hematopoietic stem cell transplantation in
patients with hematologic disorders: Chinese herbal medicine for an unmet
need</article-title>. <source>J Integr Med</source>.
<year>2016</year>;<volume>14</volume>:<fpage>322</fpage>-<lpage>335</lpage>.<pub-id pub-id-type="pmid">27641605</pub-id></mixed-citation></ref><ref id="bibr16-1534735418756736"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seggewiss</surname><given-names>R</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name></person-group>
<article-title>Immune reconstitution after allogeneic
transplantation and expanding options for immunomodulation: an
update</article-title>. <source>Blood</source>.
<year>2010</year>;<volume>115</volume>:<fpage>3861</fpage>-<lpage>3868</lpage>.<pub-id pub-id-type="pmid">20215642</pub-id></mixed-citation></ref><ref id="bibr17-1534735418756736"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moretta</surname><given-names>L</given-names></name></person-group>
<article-title>Dissecting CD56dim human NK
cells</article-title>. <source>Blood</source>.
<year>2010</year>;<volume>116</volume>:<fpage>3689</fpage>-<lpage>3691</lpage>.<pub-id pub-id-type="pmid">21071612</pub-id></mixed-citation></ref><ref id="bibr18-1534735418756736"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palmer</surname><given-names>JM</given-names></name><name><surname>Rajasekaran</surname><given-names>K</given-names></name><name><surname>Thakar</surname><given-names>MS</given-names></name><name><surname>Malarkannan</surname><given-names>S</given-names></name></person-group>
<article-title>Clinical relevance of natural killer cells
following hematopoietic stem cell transplantation</article-title>. <source>J
Cancer</source>.
<year>2013</year>;<volume>4</volume>:<fpage>25</fpage>-<lpage>35</lpage>.<pub-id pub-id-type="pmid">23386902</pub-id></mixed-citation></ref><ref id="bibr19-1534735418756736"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Non-traditional CD4+CD25&#x02013;CD69+ regulatory T
cells is correlated to leukemia relapse after allogeneic hematopoietic stem
cell transplantation</article-title>. <source>Blood</source>.
<year>2013</year>;<volume>122</volume>:<fpage>3259</fpage>.</mixed-citation></ref><ref id="bibr20-1534735418756736"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Edinger</surname><given-names>M</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Ermann</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>CD4+CD25+ regulatory T cells preserve
graft-versus-tumor activity while inhibiting graft-versus-host disease after
bone marrow transplantation</article-title>. <source>Nat Med</source>.
<year>2003</year>;<volume>9</volume>:<fpage>1144</fpage>-<lpage>1150</lpage>.<pub-id pub-id-type="pmid">12925844</pub-id></mixed-citation></ref><ref id="bibr21-1534735418756736"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Ianni</surname><given-names>M</given-names></name><name><surname>Falzetti</surname><given-names>F</given-names></name><name><surname>Carotti</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Tregs prevent GVHD and promote immune
reconstitution in HLA-haploidentical transplantation</article-title>.
<source>Blood</source>.
<year>2011</year>;<volume>117</volume>:<fpage>3921</fpage>-<lpage>3928</lpage>.<pub-id pub-id-type="pmid">21292771</pub-id></mixed-citation></ref><ref id="bibr22-1534735418756736"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perko</surname><given-names>R</given-names></name><name><surname>Kang</surname><given-names>G</given-names></name><name><surname>Sunkara</surname><given-names>A</given-names></name><name><surname>Leung</surname><given-names>W</given-names></name><name><surname>Thomas</surname><given-names>PG</given-names></name><name><surname>Dallas</surname><given-names>MH</given-names></name></person-group>
<article-title>Gamma delta T cell reconstitution is associated
with fewer infections and improved event-free survival after hematopoietic
stem cell transplantation for pediatric leukemia</article-title>.
<source>Biol Blood Marrow Transplant</source>.
<year>2015</year>;<volume>21</volume>:<fpage>130</fpage>-<lpage>136</lpage>.<pub-id pub-id-type="pmid">25445640</pub-id></mixed-citation></ref><ref id="bibr23-1534735418756736"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Godder</surname><given-names>KT</given-names></name><name><surname>Henslee-Downey</surname><given-names>PJ</given-names></name><name><surname>Mehta</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Long term disease-free survival in acute
leukemia patients recovering with increased gammadelta T cells after
partially mismatched related donor bone marrow
transplantation</article-title>. <source>Bone Marrow Transplant</source>.
<year>2007</year>;<volume>39</volume>:<fpage>751</fpage>-<lpage>757</lpage>.<pub-id pub-id-type="pmid">17450185</pub-id></mixed-citation></ref><ref id="bibr24-1534735418756736"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdel-Azim</surname><given-names>H</given-names></name><name><surname>Elshoury</surname><given-names>A</given-names></name><name><surname>Mahadeo</surname><given-names>KM</given-names></name><name><surname>Parkman</surname><given-names>R</given-names></name><name><surname>Kapoor</surname><given-names>N</given-names></name></person-group>
<article-title>Humoral immune reconstitution kinetics after
allogeneic hematopoietic stem cell transplantation in children: a maturation
block of IgM memory B cells may lead to impaired antibody immune
reconstitution</article-title>. <source>Biol Blood Marrow
Transplant</source>.
<year>2017</year>;<volume>23</volume>:<fpage>1437</fpage>-<lpage>1446</lpage>.<pub-id pub-id-type="pmid">28495643</pub-id></mixed-citation></ref><ref id="bibr25-1534735418756736"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Avanzini</surname><given-names>MA</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Dos Santos</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>B lymphocyte reconstitution after hematopoietic
stem cell transplantation: functional immaturity and slow recovery of memory
CD27+ B cells</article-title>. <source>Exp Hematol</source>.
<year>2005</year>;<volume>33</volume>:<fpage>480</fpage>-<lpage>486</lpage>.<pub-id pub-id-type="pmid">15781339</pub-id></mixed-citation></ref><ref id="bibr26-1534735418756736"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ogonek</surname><given-names>J</given-names></name><name><surname>Juric</surname><given-names>MK</given-names></name><name><surname>Ghimire</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Immune reconstitution after allogeneic
hematopoietic stem cell transplantation</article-title>. <source>Front
Immunol</source>.
<year>2016</year>;<volume>7</volume>:<fpage>507</fpage>.<pub-id pub-id-type="pmid">27909435</pub-id></mixed-citation></ref><ref id="bibr27-1534735418756736"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>V</given-names></name><name><surname>Iturraspe</surname><given-names>JA</given-names></name><name><surname>Tzolas</surname><given-names>AC</given-names></name><name><surname>Meier-Kriesche</surname><given-names>HU</given-names></name><name><surname>Schold</surname><given-names>J</given-names></name><name><surname>Wingard</surname><given-names>JR</given-names></name></person-group>
<article-title>Low dendritic cell count after allogeneic
hematopoietic stem cell transplantation predicts relapse, death, and acute
graft-versus-host disease</article-title>. <source>Blood</source>.
<year>2004</year>;<volume>103</volume>:<fpage>4330</fpage>-<lpage>4335</lpage>.<pub-id pub-id-type="pmid">14962904</pub-id></mixed-citation></ref><ref id="bibr28-1534735418756736"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leon</surname><given-names>AC</given-names></name><name><surname>Davis</surname><given-names>LL</given-names></name><name><surname>Kraemer</surname><given-names>HC</given-names></name></person-group>
<article-title>The role and interpretation of pilot studies in
clinical research</article-title>. <source>J Psychiatr Res</source>.
<year>2011</year>;<volume>45</volume>:<fpage>626</fpage>-<lpage>629</lpage>.<pub-id pub-id-type="pmid">21035130</pub-id></mixed-citation></ref><ref id="bibr29-1534735418756736"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henden</surname><given-names>AS</given-names></name><name><surname>Hill</surname><given-names>GR</given-names></name></person-group>
<article-title>Cytokines in graft-versus-host
disease</article-title>. <source>J Immunol</source>.
<year>2015</year>;<volume>194</volume>:<fpage>4604</fpage>-<lpage>4612</lpage>.<pub-id pub-id-type="pmid">25934923</pub-id></mixed-citation></ref><ref id="bibr30-1534735418756736"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooke</surname><given-names>KR</given-names></name><name><surname>Hill</surname><given-names>GR</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name><etal>et al</etal></person-group>
<article-title>Tumor necrosis factor-alpha production to
lipopolysaccharide stimulation by donor cells predicts the severity of
experimental acute graft-versus-host disease</article-title>. <source>J Clin
Invest</source>.
<year>1998</year>;<volume>102</volume>:<fpage>1882</fpage>-<lpage>1891</lpage>.<pub-id pub-id-type="pmid">9819375</pub-id></mixed-citation></ref><ref id="bibr31-1534735418756736"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Piguet</surname><given-names>PF</given-names></name><name><surname>Grau</surname><given-names>GE</given-names></name><name><surname>Allet</surname><given-names>B</given-names></name><name><surname>Vassalli</surname><given-names>P</given-names></name></person-group>
<article-title>Tumor necrosis factor/cachectin is an effector
of skin and gut lesions of the acute phase of graft-vs.-host
disease</article-title>. <source>J Exp Med</source>.
<year>1987</year>;<volume>166</volume>:<fpage>1280</fpage>-<lpage>1289</lpage>.<pub-id pub-id-type="pmid">3316469</pub-id></mixed-citation></ref><ref id="bibr32-1534735418756736"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Dutcher</surname><given-names>JP</given-names></name><etal>et al</etal></person-group>
<article-title>High-dose recombinant interleukin 2 therapy for
patients with metastatic melanoma: analysis of 270 patients treated between
1985 and 1993</article-title>. <source>J Clin Oncol</source>.
<year>1999</year>;<volume>17</volume>:<fpage>2105</fpage>-<lpage>2116</lpage>.<pub-id pub-id-type="pmid">10561265</pub-id></mixed-citation></ref><ref id="bibr33-1534735418756736"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koreth</surname><given-names>J</given-names></name><name><surname>Matsuoka</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><etal>et al</etal></person-group>
<article-title>Interleukin-2 and regulatory T cells in
graft-versus-host disease</article-title>. <source>N Engl J Med</source>.
<year>2011</year>;<volume>365</volume>:<fpage>2055</fpage>-<lpage>2066</lpage>.<pub-id pub-id-type="pmid">22129252</pub-id></mixed-citation></ref><ref id="bibr34-1534735418756736"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saadoun</surname><given-names>D</given-names></name><name><surname>Rosenzwajg</surname><given-names>M</given-names></name><name><surname>Joly</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Regulatory T-cell responses to low-dose
interleukin-2 in HCV-induced vasculitis</article-title>. <source>N Engl J
Med</source>.
<year>2011</year>;<volume>365</volume>:<fpage>2067</fpage>-<lpage>2077</lpage>.<pub-id pub-id-type="pmid">22129253</pub-id></mixed-citation></ref><ref id="bibr35-1534735418756736"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>EJ</given-names></name></person-group>
<article-title>Related haploidentical donors are a better
choice than matched unrelated donors: point</article-title>. <source>Blood
Adv</source>.
<year>2017</year>;<volume>1</volume>:<fpage>397</fpage>-<lpage>400</lpage>.<pub-id pub-id-type="pmid">29296954</pub-id></mixed-citation></ref><ref id="bibr36-1534735418756736"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alho</surname><given-names>AC</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><name><surname>Chammas</surname><given-names>MJ</given-names></name><etal>et al</etal></person-group>
<article-title>Unbalanced recovery of regulatory and effector T
cells after allogeneic stem cell transplantation contributes to chronic
GVHD</article-title>. <source>Blood</source>.
<year>2016</year>;<volume>127</volume>:<fpage>646</fpage>-<lpage>657</lpage>.<pub-id pub-id-type="pmid">26670634</pub-id></mixed-citation></ref><ref id="bibr37-1534735418756736"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burns</surname><given-names>DM</given-names></name><name><surname>Tierney</surname><given-names>R</given-names></name><name><surname>Shannon-Lowe</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Memory B-cell reconstitution following
allogeneic hematopoietic stem cell transplantation is an EBV-associated
transformation event</article-title>. <source>Blood</source>.
<year>2015</year>;<volume>126</volume>:<fpage>2665</fpage>-<lpage>2675</lpage>.<pub-id pub-id-type="pmid">26450987</pub-id></mixed-citation></ref><ref id="bibr38-1534735418756736"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abboud</surname><given-names>I</given-names></name><name><surname>Peraldi</surname><given-names>MN</given-names></name><name><surname>Hingorani</surname><given-names>S</given-names></name></person-group>
<article-title>Chronic kidney diseases in long-term survivors
after allogeneic hematopoietic stem cell transplantation: monitoring and
management guidelines</article-title>. <source>Semin Hematol</source>.
<year>2012</year>;<volume>49</volume>:<fpage>73</fpage>-<lpage>82</lpage>.<pub-id pub-id-type="pmid">22221787</pub-id></mixed-citation></ref><ref id="bibr39-1534735418756736"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ellis</surname><given-names>MJ</given-names></name><name><surname>Parikh</surname><given-names>CR</given-names></name><name><surname>Inrig</surname><given-names>JK</given-names></name><name><surname>Kanbay</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>UD</given-names></name></person-group>
<article-title>Chronic kidney disease after hematopoietic cell
transplantation: a systematic review</article-title>. <source>Am J
Transplant</source>.
<year>2008</year>;<volume>8</volume>:<fpage>2378</fpage>-<lpage>2390</lpage>.<pub-id pub-id-type="pmid">18925905</pub-id></mixed-citation></ref><ref id="bibr40-1534735418756736"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>BC</given-names></name><name><surname>Choi</surname><given-names>JB</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group>
<article-title>Rehmannia glutinosa ameliorates the progressive
renal failure induced by 5/6 nephrectomy</article-title>. <source>J
Ethnopharmacol</source>.
<year>2009</year>;<volume>122</volume>:<fpage>131</fpage>-<lpage>135</lpage>.<pub-id pub-id-type="pmid">19146934</pub-id></mixed-citation></ref><ref id="bibr41-1534735418756736"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group>
<article-title>Chinese herbal medicine in the treatment of
chronic kidney disease</article-title>. <source>Adv Chronic Kidney
Dis</source>.
<year>2005</year>;<volume>12</volume>:<fpage>276</fpage>-<lpage>281</lpage>.<pub-id pub-id-type="pmid">16010642</pub-id></mixed-citation></ref><ref id="bibr42-1534735418756736"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parimon</surname><given-names>T</given-names></name><name><surname>Au</surname><given-names>DH</given-names></name><name><surname>Martin</surname><given-names>PJ</given-names></name><name><surname>Chien</surname><given-names>JW</given-names></name></person-group>
<article-title>A risk score for mortality after allogeneic
hematopoietic cell transplantation</article-title>. <source>Ann Intern
Med</source>.
<year>2006</year>;<volume>144</volume>:<fpage>407</fpage>-<lpage>414</lpage>.<pub-id pub-id-type="pmid">16549853</pub-id></mixed-citation></ref><ref id="bibr43-1534735418756736"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sorror</surname><given-names>ML</given-names></name><name><surname>Maris</surname><given-names>MB</given-names></name><name><surname>Storb</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Hematopoietic cell transplantation
(HCT)-specific comorbidity index: a new tool for risk assessment before
allogeneic HCT</article-title>. <source>Blood</source>.
<year>2005</year>;<volume>106</volume>:<fpage>2912</fpage>-<lpage>2919</lpage>.<pub-id pub-id-type="pmid">15994282</pub-id></mixed-citation></ref></ref-list></back></article>